Abiraterone in metastatic prostate cancer without previous chemotherapy

Charles J. Ryan, Matthew R. Smith, Johann S. De Bono, Arturo Molina, Christopher J. Logothetis, Paul De Souza, Karim Fizazi, Paul Mainwaring, Josep M. Piulats, Siobhan Ng, Joan Carles, Peter F.A. Mulders, Ethan Basch, Eric J. Small, Fred Saad, Dirk Schrijvers, Hendrik Van Poppel, Som D. Mukherjee, Henrik Suttmann, Winald R. GerritsenThomas W. Flaig, Daniel J. George, Evan Y. Yu, Eleni Efstathiou, Allan Pantuck, Eric Winquist, Celestia S. Higano, Mary Ellen Taplin, Youn Park, Thian Kheoh, Thomas Griffin, Howard I. Scher, Dana E. Rathkopf

Research output: Contribution to journalArticlepeer-review

2287 Scopus citations


Background: Abiraterone acetate, an androgen biosynthesis inhibitor, improves overall survival in patients with metastatic castration-resistant prostate cancer after chemotherapy. We evaluated this agent in patients who had not received previous chemotherapy. Methods: In this double-blind study, we randomly assigned 1088 patients to receive abiraterone acetate (1000 mg) plus prednisone (5 mg twice daily) or placebo plus prednisone. The coprimary end points were radiographic progression-free survival and overall survival. Results: The study was unblinded after a planned interim analysis that was performed after 43% of the expected deaths had occurred. The median radiographic progressionfree survival was 16.5 months with abiraterone - prednisone and 8.3 months with prednisone alone (hazard ratio for abiraterone - prednisone vs. prednisone alone, 0.53; 95% confidence interval [CI], 0.45 to 0.62; P<0.001). Over a median follow-up period of 22.2 months, overall survival was improved with abiraterone - prednisone (median not reached, vs. 27.2 months for prednisone alone; hazard ratio, 0.75; 95% CI, 0.61 to 0.93; P = 0.01) but did not cross the efficacy boundary. Abiraterone - prednisone showed superiority over prednisone alone with respect to time to initiation of cytotoxic chemotherapy, opiate use for cancer-related pain, prostate-specific antigen progression, and decline in performance status. Grade 3 or 4 mineralocorticoid-related adverse events and abnormalities on liver-function testing were more common with abiraterone-prednisone. Conclusions: Abiraterone improved radiographic progression-free survival, showed a trend toward improved overall survival, and significantly delayed clinical decline and initiation of chemotherapy in patients with metastatic castration-resistant prostate cancer.

Original languageEnglish (US)
Pages (from-to)138-148
Number of pages11
JournalNew England Journal of Medicine
Issue number2
StatePublished - Jan 10 2013
Externally publishedYes


Dive into the research topics of 'Abiraterone in metastatic prostate cancer without previous chemotherapy'. Together they form a unique fingerprint.

Cite this